APLT Applied Therapeutics
- 4.760
- +0.230+5.08%
- 4.702
- -0.058-1.21%
Applied Therapeutics News
Applied Therapeutics Welcomes Dale Hooks as New CCO
Express News | Applied Therapeutics Appoints Dale Hooks as Chief Commercial Officer
RBC Capital Sticks to Their Buy Rating for Applied Therapeutics (APLT)
Express News | RBC Capital Reiterates Outperform on Applied Therapeutics, Maintains $12 Price Target
CNDT, CHRS and OM Are Among Materials Movers
Express News | Applied Therapeutics Plans To Present Results From Phase 3 ARISE-HF Study In Diabetic Cardiomyopathy At ACC 2024
Analysts Offer Insights on Healthcare Companies: Disc Medicine (IRON), Applied Therapeutics (APLT) and Vincerx Pharma Inc (VINC)
FDA Presses Delay Button For Applied Therapeutics' First Potential Marketed Drug For Rare Disease
Thursday, the FDA extended the review period for Applied Therapeutics Inc's (NASDAQ:APLT) New Drug Application (NDA) for govorestat (AT-007) for the treatment of Classic Galactosemia by three months.
12 Health Care Stocks Moving In Monday's Pre-Market Session
GainersGalera Therapeutics (NASDAQ:GRTX) shares moved upwards by 62.8% to $0.23 during Monday's pre-market session. The market value of their outstanding shares is at $12.3 million. As per the news, t
Oxford Industries Posts Weak Results, Joins Applied Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining by over 100 points on Monday. Shares of Oxford Industries, Inc. (NYSE:OXM) fell sharply in today's pre-market trading as the
12 Health Care Stocks Moving In Friday's After-Market Session
GainersQilian Intl Hldg Gr (NASDAQ:QLI) shares rose 63.8% to $1.04 during Friday's after-market session. The market value of their outstanding shares is at $37.1 million. Sunshine Biopharma (NASDAQ:SB
Applied Therapeutics Says FDA Extends Review Period Of NDA For Govorestat
Stocks to Watch: Torrid, Applied Therapeutics, Doma
By Ben Glickman Torrid Holdings posted loss in the fiscal fourth quarter which was narrower than analysts expected. The clothing brand's sales topped estimates and were ahead of guidance, with Chief
Applied Therapeutics Shares Slip 13% After FDA Extends Drug Review
By Ben Glickman Shares of Applied Therapeutics sank after regulators extended the company's target action date for its new drug application. The stock was down 13% to $5.90 in after-hours trading on
FDA Extends Review Period for Applied Therapeutics Genetic Disease Treatment
By Ben Glickman Applied Therapeutics said regulators had extended the period for reviewing its application for a rare metabolic disease treatment. The biopharmaceutical company said Thursday that th
Express News | Applied Therapeutics Shares Are Trading Lower After the Company Announced That the FDA Extended the Review Period for the NDA for Govorestat for the Treatment of Classic Galactosemia by Three Months
Applied Therapeutics Says FDA Has Extended Review Period For NDA For Govorestat (AT-007) For Treatment Of Classic Galactosemia By Three Months; PDUFA Target Action Date November 28, 2024
The FDA notified Applied Therapeutics that it required additional time to review supplemental analyses of previously submitted data that had been provided by Applied in response to the FDA's routine i
Applied Therapeutics Price Target Announced at $12.00/Share by RBC Capital
Applied Therapeutics Price Target Announced at $12.00/Share by RBC Capital
RBC Capital Initiates Coverage On Applied Therapeutics With Outperform Rating, Announces Price Target of $12
RBC Capital analyst Brian Abrahams initiates coverage on Applied Therapeutics (NASDAQ:APLT) with a Outperform rating and announces Price Target of $12.
RBC Initiates Applied Therapeutics at Outperform, Speculative Risk With $12 Price Target, Sees Lead Drug Govorestat 'Well-Positioned for Success'
Applied Therapeutics (APLT) has an average investment rating of buy among analysts polled by Capital IQ, with price targets ranging from $7 to $14. Price: 7.11, Change: +0.36, Percent Change: +5.33
Analysis
Price Target
No Data
